investigational immunotherapy MPDL3280A doubled the likelihood of survival compared with chemotherapy in people with a specific type of lung cancer

… of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed … of Breakthrough Therapy Designation in lung cancer. Roche currently has three Phase … tumour cells. About non-small cell lung cancer Lung cancer is the leading cause of … all cases. About Roche in lung cancer Lung cancer is a major area of …